Olmesartan Medoxomil/Rosuvastatin 20/5 mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Korea Prime Pharm Co., Ltd.
MFDS item code 202003984 · Approved 2020.05.28
This product's status changed to Approval withdrawn on 2024.09.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension, improvement of dyslipidemia, suppression of atherosclerotic progression and cardiovascular disease risk
This medication is used for patients who require simultaneous administration of olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil primarily helps in the treatment of essential hypertension. Rosuvastatin is used as an adjunct when dietary therapy and exercise do not control hypercholesterolemia and mixed dyslipidemia. Additionally, it helps manage lipid levels in patients with familial hypercholesterolemia or dysbetalipoproteinemia. This medication lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis and reducing the risk of stroke, myocardial infarction, and arterial revascularization procedures in patients with specific cardiovascular risk factors. Therefore, it is used to improve cardiovascular health by managing blood pressure and cholesterol.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is necessary when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may be switched to this medicine (a fixed-dose combination with the same amount of each active ingredient) for convenience.
Safety and efficacy have not been established in children under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It is safest not to use this medication in individuals with allergies to its components, pregnant or breastfeeding women, or fertile women not using adequate contraception. Patients with severely impaired kidney function, those receiving kidney dialysis, patients with severe liver impairment, biliary obstruction, and those with muscle disease should not be administered this medication. Patients with a high risk of muscle-related side effects, such as those with moderate to severe kidney damage, hypothyroidism, a history of muscle disease, alcoholics, and those taking certain concomitant medications should consult their healthcare provider before using this medication. This medication contains lactose and should not be administered to patients with lactose intolerance or certain metabolic disorders. Patients with low blood pressure or reduced body sodium may experience hypotension symptoms when starting this medication; therefore, it is important to monitor their condition closely before administration and during treatment. Patients with dependent kidney function or kidney transplant recipients should have regular blood tests to check kidney function and electrolyte levels. If symptoms such as muscle pain, muscle weakness, or muscle cramps occur during the use of this medication, the healthcare provider should be notified immediately, and treatment should be discontinued if severe. Black patients with hypertension may experience a reduced blood pressure-lowering effect, so treatment efficacy should be closely monitored. This medication may affect liver function, so patients with a history of liver disease or excessive alcohol consumption should regularly undergo liver function tests. When performing activities that involve risk, such as driving or operating machinery, caution is advised, as side effects such as dizziness or drowsiness may occur. Interactions may occur when taken with other medications; therefore, all medications being taken should be reported to healthcare providers, especially when combined with potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, certain antibiotics, and antifungals. Women of childbearing potential should use adequate contraception during treatment and immediately discontinue if pregnancy is suspected or confirmed. Breastfeeding women should avoid or discontinue this medication because it may be transferred into breast milk and affect the infant. The safety and efficacy of this medication in children under 18 years have not been fully established and are therefore not recommended for pediatric use. Elderly patients may have increased blood concentrations of this medication, requiring dosage adjustments and monitoring for side effects. In the event of an overdose, symptoms such as hypotension, palpitations, and bradycardia may occur; immediate medical attention is necessary.
ALT elevation, AST elevation, increased serum creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuromuscular disease, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, rhabdomyolysis, hyperkalemia, acute kidney failure, hair loss, itching, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, hypertension, low back pain, increased serum creatinine, diarrhea, chest pain, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture and should be stored in a tightly sealed container. Additionally, it should be kept away from excessively cold or hot temperatures and stored at room temperature between 1°C and 30°C.
White or yellowish round film-coated tablets
30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Korea Prime Pharm Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.